Generic Name:
Cetuximab
Project Status:
Cancelled
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Erbitux
Project Line:
Reimbursement Review
Project Number:
PC0128-000
NOC Date:
Details
Strength:
2 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Left Sided Metastatic Colorectal Cancer
Funding Request:
For the first-line treatment of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours
Review Status:
Cancelled
Sponsor:
Eli Lilly Canada Inc.
Clarification:
The submitter notified pCODR that they will not be filing the submission.